Commercially, Ipsen is not yet present on the hematology market. Leveraging its expertise in protein engineering, the Group has launched a major research programme in hemostasis (blood coagulation).
Hemophilia is a hereditary genetic disease characterized by reduced blood clotting. Hemophilia A is caused by a deficiency of factor VIII, while hemophilia B is caused by a deficiency of factor IX. The condition affects one new born in 10,000; 85% of patients have hemophilia A and 15% have hemophilia B. Approximately 50% of hemophilia subjects suffer from severe illness entailing frequent spontaneous hemorrhaging episodes. Depending on their location, hemorrhages may have serious consequences and can be fatal (such as intracerebral hemorrhage). If not treated appropriately, hemorrhage into the joints (hemarthrosis) can cause breakdown and eventual loss of the articular cartilage entailing a chronic debilitating condition.